MDWD logo

MediWound Ltd. (MDWD)

$13.61

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MDWD

Market cap

$195850853

EPS

-2.1

P/E ratio

--

Price to sales

9.55

Dividend yield

--

Beta

0.075295

Price on MDWD

Previous close

$13.68

Today's open

$13.60

Day's range

$13.60 - $14.10

52 week range

$11.80 - $19.70

Profile about MDWD

CEO

Ofer Gonen

Employees

121

Headquarters

Yavne,

Exchange

NASDAQ Global Market

Shares outstanding

14390217

Issue type

Common Stock

MDWD industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MDWD

MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026

MediWound to Host Virtual KOL Event on EscharEx ® Phase III VALUE Study and Commercial Opportunity on December 2, 2026 Leading wound care experts to discuss Phase II clinical evidence, the pivotal Phase III VALUE study, and the estimated $1.05 billion U.S. annual peak sales potential YAVNE, Israel, November 16, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, December 2, 2026, at 11:00 a.m.

news source

GlobeNewsWire • Nov 16, 2026

news preview

What MediWound (MDWD) Said on Its Q3 Earnings Call

MediWound NASDAQ: MDWD reported lower third-quarter revenue and a wider net loss as it increased spending on its late-stage EscharEx trial, while executives said manufacturing constraints continue to limit sales of its burn treatment NexoBrid.

news source

MarketBeat • Nov 12, 2026

news preview

MediWound Ltd. (MDWD) Q3 2026 Earnings Call Transcript

MediWound Ltd. (MDWD) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 12, 2026

news preview

MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update

EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027

news source

GlobeNewsWire • Nov 12, 2026

news preview

MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates

MediWound (MDWD) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.24 per share a year ago.

news source

Zacks Investment Research • Nov 12, 2026

news preview

MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares

MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 5, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the closing of its previously announced underwritten public offering of 1,380,000 ordinary shares, including 180,000 ordinary shares issued pursuant to the full exercise of the underwriter's option to purchase additional ordinary shares, at a public offering price of $12.50 per ordinary share.

news source

GlobeNewsWire • Nov 5, 2026

news preview

MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last?

MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

news source

Zacks Investment Research • Nov 5, 2026

news preview

MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares

MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has entered into an underwriting agreement with H.C.

news source

GlobeNewsWire • Nov 3, 2026

news preview

MediWound to Report Third Quarter 2026 Financial Results

MediWound to Report Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, November 12 th at 8:30 a.m. Eastern Time YAVNE, Israel, October 29, 2026 -- MediWound Ltd.

news source

GlobeNewsWire • Oct 29, 2026

news preview

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid ®

news source

GlobeNewsWire • Sep 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in MediWound Ltd.

Open an M1 investment account to buy and sell MediWound Ltd. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MDWD on M1